印度制药公司预计在利压力下, 成长将会适度. Indian pharma firms expect modest growth amid margin pressure.

印度制药公司预计3月季度销售额将以11%的速度增长, Indian pharma companies expect modest sales growth of 11% in the March quarter, driven by a strong domestic market. 然而,由于成本上升,美国的定价压力以及gRevlimid等关键药物的缺失,HDFC证券预计EBITDA利率将下降110个基点. However, HDFC Securities predicts a 110 basis point drop in EBITDA margins due to rising costs, US pricing pressure, and the absence of key drugs like gRevlimid. 医院和零售药房部门预计将有显著增长,诊断领域也表现强. The hospital and retail pharmacy sectors are projected to grow significantly, while diagnostics also show robust performance.